ArticleBritish journal of haematology2025
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS.
Emma Searle et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.